Infertility/Sterility Clinical Trial
Official title:
Cetrorelix and Ganirelix Flexible Protocol for In Vitro Fertilization: a Prospective Randomized Trial
Recombinant gonadotropins are currently used for ovarian stimulation in women undergoing to
IVF for infertility. Recently new flexible protocols have been introduced: the "single dose"
and "multiple dose" protocol. The single dose protocol is performed just using Cetrorelix by
the administration of a single injection of Cetrorelix 3 mg subcutaneous when the lead
follicle is ≥ 14 mm. The multiple dose protocol consider the daily administration of
Cetrorelix 0.25 mg subcutaneous or Ganirelix 0.25 mg subcutaneous when the lead follicle is ≥
14 mm and until the realization of hCG criteriaThere are few data from letterature about the
comparison of the efficacy in pitituary suppression and pregnancy outcome of Ganirelix and
Cetrorelix.
Objective: to compare the efficacy in pituitary gonadotropin suppression and IVF outcome of
multiple dose flexible gonadotrophin-releasing hormone (GnRH) antagonist administration
according to follicular size using daily injection of Cetrorelix or Ganirelix.
Interventions : patients are randomly assigned in to Cetrorelix acetate group or Ganirelix
acetate group. Multiple dose of Cetrorelix acetate (0.25 mg) or multiple dose of Ganirelix
acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are
met.Oocyte maturation trigger is performed by the administration of subcutaneous r-hCG (250
μg) or of intramuscular hCG (10,000 IU). After 36 hour transvaginal oocyte retrieval is
performed followed by ICSI and embrio transfer (72 hours later).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03348865 -
Fertility Life Counselling Aid- FeLiCiA
|
N/A | |
| Completed |
NCT03118219 -
Positive Adjustment Coping Intervention
|
N/A | |
| Enrolling by invitation |
NCT03350009 -
Markers in Follicular Fluid and in Embryo Culture Medium as a Marker of Oocyte and Embryo Quality
|